Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
- PMID: 35660253
- DOI: 10.1016/j.ejca.2022.03.044
Re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Comment on
-
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.Eur J Cancer. 2022 Feb;162:148-157. doi: 10.1016/j.ejca.2021.12.009. Epub 2022 Jan 5. Eur J Cancer. 2022. PMID: 34998046
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
